Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 with or without Cetrelimab vs BCG in BCG-naive High-Risk Non-Muscle Invasive Bladder Cancer
NCT05714202Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Sep 2029
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 21
01
Overview
A Phase 3 trial of gemcitabine-releasing intravesical system in non-muscle-invasive bladder cancer (NMIBC), sponsored by Janssen Pharmaceutical. Started Mar 2023; status: active, not recruiting.
02
Drugs
gemcitabine-releasing intravesical system
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05714202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714202.